Programme | Wednesday 1 June 2011 Venue | Winkel van Sinkel, Utrecht 13.00 - 13.15 hrs | Registration & Coffee/Tea 13.15 - 13.30 hrs | Welcome by Chrétien Herben, NGI Valorisation 13.30 - 14.00 hrs 1-on-1 Expert session 13.30 - 15.00 hrs Workshop 1 | 14.00 - 14.30 hrs Coaching and Training 1-on-1 Expert session 14.30 - 15.00 hrs 1-on-1 Expert session 15.00 - 15.15 hrs | Break 15.15 - 15.45 hrs 1-on-1 Expert session 15.15 - 16.45 hrs 15.45 - 16.15 hrs 1-on-1 Expert session Workshop 2 | Financial Support 16.15 - 16.45 hrs 1-on-1 Expert session 16.45 - 17.00 hrs | Break 17.00 - 17.30 hrs 17.00 - 17.30 hrs Workshop 3 | Networking 1-on-1 Expert session 17.30 - 17.45 hrs | Winner announcement Venture Challenge Spring 2011 17.45 - 18.30 hrs | Networking with Drinks & Bites Version February 2011 Workshops | Wednesday 1 June 2011 Winkel van Sinkel, Utrecht 13.30 – 15.00 hrs Workshop 1 | Coaching and Training As a starting entrepreneur, you often find yourself in new unknown situations where you would appreciate the advice or assistance of someone with experience. Someone who has dealt with the challenges you face or can bring you into contact with others who can open doors and prevent you from making 'beginner' mistakes. In short, a coach. But how do you find such an individual, why would an experienced person help you, what can you expect from a coach and what should you not expect? In this workshop, experienced life sciences coaches will offer their interpretation of coaching and explain why they do it. Also, entrepreneurs who have experience with a coach will talk about the resulting benefits and how their coach has been of value to them. Under the chairmanship of Pedro Tetteroo, who himself is an experienced coach, an interactive discussion will be conducted with coaches and entrepreneurs. 15.15 – 16.45 hrs Workshop 2 | Financial Support In this interactive workshop, Manja Bouman (CEO Kiadis Pharma) and Jaap Koopman (CSO and ex-CEO Profibrix) will explain what it's really like to be CEO of a company in the life sciences sector. Not just the kicks, but also the near death experiences. Which qualities do you require - or need to develop – to stand tall in an environment where the chances of success are small, loyalty is fleeting and money expensive? Can the soft powers prevail? Hard Euros, soft powers Hey man, what's your style, How d'you get your kicks for livin', Hey man, what's your style, How d'you get your adrenalin flowin' Lou Reed, Kicks Moderators are Carine van den Brink and Otto Postma (MedSciences Capital), who will be happy to share their highs and lows with you. Come and learn! 17.00 – 17.30 hrs Workshop 3 | Networking Building up and maintaining an efficient network in the life sciences is not only necessary, it's also good fun. That was the vision shared by a number of entrepreneurs in the life sciences ten years ago established yels.net, or in full: Young Entrepreneurs in de Life Sciences. Yels.net will be relaunched under the name Niaba BioBusiness Entrepreneurs, a network of and for entrepreneurs in the biotechnology sector. With presentations by the founders of yels.net and a vision of the future. Don't miss it! Expert profiles Winkel van Sinkel, Utrecht Harrold van Barlingen Function: Managing director Organisation: Thuja Capital Management B.V. Email: Harrold.email@example.com Short biography: Dr. Harrold van Barlingen is the Managing Partner and Founder of Thuja Capital. Prior to founding Thuja Capital, he headed the life science effort of AlpInvest Partners managing a portfolio of over 30 companies. Harrrold joined AlpInvest Partners in 2001, from the Boston Consulting Group ('BCG'), where he worked as a consultant in management and strategy. Before BCG, Harrold was acting head of the continental activities of the Lewin Group (a Quintiles subsidiary), an international firm specialized in the field of health economy. Harrold holds a Master of Science degree in Medical Biology and a Ph.D. in Medicine, both from the University of Utrecht. From 1991-1992 he was a visiting scientist at the University of Chicago, USA. Harrold is the author of a wide-variety of peer-reviewed scientific and pharmaco-economics papers. Harrold serves on the supervisory boards of Galapagos (GLPG, Euronext), Okapi Sciences and arGEN-X, furthermore he represents AlpInvest Partners at the board of Curacyte. Expertise: Financing Interests: Therapies, Drug discovery, Diagnostics, Medical Devices Geert-Jan Mulder Function: Partner Organisation: Forbion Capital Partners Email: firstname.lastname@example.org Short biography: Geert-Jan Mulder MD is an experienced life sciences investor and led multiple deals in both Europe and US, where he was involved in 17 investments in this sector. Based on his background in clinical development he assists various Forbion portfolio companies in building their clinical development strategies Geert-Jan is General Partner at Forbion Life Sciences, a Netherlands based venture capital firm which was spun out of ABN AMRO Capital in 2006. Dr Mulder is a medical doctor and received his medical degree from the University of Utrecht in the Netherlands. In 2001, he was registered as a Pharmaceutical Physician. Prior to joining ABN AMRO Capital in 2001, he was Clinical Research Manager for The Netherlands for Byk Gulden (now Nycomed), where his department dealt with the design and execution of numerous phase 1, 2 and 3 clinical trials. Prior to joining Byk Gulden he was with Searle (now Pfizer) working in the field of arthritis & pain as a Medical Adviser, being involved in the clinical development as well as local and European advocate development in the pre-launch roll-out for Celebrex (celecoxib). Dr Mulder currently serves on the board of Promedior Inc, Exosome Diagnostics Inc, bluebirdbio (formerly Genetics Pharmaceuticals), Provecica Ltd. and PanGenetics BV. Before going public he represented AAC LS on the board of Acorda Therapeutics where he was part of the Fampridine-SR board panel to evaluate a new clinical endpoint in Multiple Sclerosis, which became the basis for their successful pivotal phase III trial. Geert-Jan's accomplishments include: i) the sale of Pangenetics in 2009 for USD 190 million, as a member of the M&A committee, ii) successful IPO of Acorda Therapeutics in 2006, where he supported the company in various areas, iii) end of 2010 the merger between Transave Inc. and Insmed (INSM - NASDAQ), as a member of the M&A committee. In addition to his position as general partner at Forbion, Geert-Jan provides scientific feedback to a number of portfolio companies and actively works together with management teams in various task forces or advisory committees to add value to their clinical, regulatory programs and corporate strategy. His efforts supported robust development programs, IND filings, a Special Protocol Approval (SPA) by the FDA and Orphan designation for 3 potential treatments in the US as well as EU. Prior to joining the ABN AMRO Capital Life Sciences (AAC LS) team in 2001, he was Clinical Research Manager for The Netherlands for Byk Gulden (now Nycomed), where his department dealt with the design and execution of numerous phase I/IIa, IIb, IIIa and IIIb clinical trials in the fields of Gastroenterology, Respiratory Medicine (asthma and COPD), Intensive Care Medicine and Imaging. He was a Member of the Global Medical Marketing group of the Respiratory Franchise and was involved in the line extension program for Pantozol (pantoprazole). Prior to joining Byk Gulden he was with Searle (now Pfizer) working in the field of Arthritis & Pain as a Medical Adviser, being involved in the clinical development as well as local and European advocate development in the pre-launch roll-out for Celebrex (celecoxib). Geert-Jan received his Medical Degree from the University of Utrecht in the Netherlands. During and after his internships he spent two years as a clinician in Obstetrics and Gynaecology at the University Medical Center of Utrecht (UMC). In 2001, Geert-Jan was awarded his Registration as Pharmaceutical Physician. Expertise: Financing, Clinical Development strategy, Medical Marketing Interests: Drug Development , Diagnostics, Medical Devices, Therapies, Drug discovery Biodiversity, Food Otto Postma Function: Senior Investment Manager Organisation: MedSciences Capital (MSC) Email: email@example.com Short biography: Before joining MSC in 2007, Otto was an independent consultant providing strategic services to start-ups and research institutions in the field of medical life sciences (2000-2006). In 1998, Otto founded and managed Pharming Healthcare, Inc., the US subsidiary of Pharming Group NV, which Otto co-founded in 1988. Otto held various senior management positions at Pharming, mainly in the fields of commercial development and corporate strategy. In 1984, Otto co-founded the Center for Bio-Pharmaceutical Sciences at Leiden University and became its first Industrial Liaison Officer. Otto obtained an MS Chemistry (cum laude) from Utrecht University. Expertise: VC financing, Corporate strategy, Commercial & Business Development. Interests: MSC (a VC investment fund of merchant bank Kempen & Co) is interested in early- to mid-stage companies developing innovative therapies, diagnostics, or medical devices. See www.medsciencescapital.com. Kees Recourt Function: Investment Manager Organisation: Mibiton Email: firstname.lastname@example.org Short biography: BSc in Electronics (1981, Breda), MSc and PhD in Molecular Biology (Utrecht and Leiden 1982-1991). Eight years contract research experience for Agrotech and Food industry (ATO-DLO, 1991-1999). Seven years employed at a commercial technology transfer company (Licentec owned by ABN-AMRO and NPM Capital) analysing IP, performing Due Diligence of medical- and agro Life Sciences start-up companies, including early stage management (1999-2006). Five years experience as investment manager at Mibiton (€ 8 million capital invested in equipment and facilities). Owner of Recourt Life Sciences since 2006 providing business services in the field of young LS companies. Expertise: Financing (equipment), IP (general), Start-Up management Interests: Life Sciences and High Tech Sanne Weijzen Function: Partner Organisation: Aglaia BioMedical Ventures Email: Weijzen@aglaia-biomedical.com Short biography: After obtaining her M.Sc. in biomedical sciences at Leiden University (The Netherlands) in 1998, she started her Ph.D. research in cancer immunology/cancer biology at the Cardinal Bernardin Cancer Center in Chicago (USA). Following the completion of her thesis, she held a post-doc position at Utrecht University (The Netherlands) from 2002 to early 2006, working on signal transduction in cancer. In 2006 she joined Aglaia BioMedical Ventures as a business analyst, after which she became an investment manager and recently partner. Within Aglaia, she is responsible for evaluation of new opportunities and for the supervision of some of Aglaia‟s portfolio companies. She is a member on the Board of Directors of InteRNA Technologies. Expertise: Business Specialties: Determination of business strategy of early start-up companies; Lining up business strategy with IP strategy and project strategy; Design and control of IP strategy; IP management/coordination Scientific specialties: Tumor immunology/immunotherapy Tumor biology miRNA biology Cell signaling pathways Functional cancer assays Interests: Therapeutic drug development in oncology. Edward van Wezel Function: Managing Partner Organisation: BioGeneration Ventures Email: email@example.com Short biography: Edward has extensive international expertise in small and large pharma and biotech companies He started his industrial career as process engineer for Chiron Inc. where he was involved in setting up manufacturing facilities in Amsterdam for the production of Beta-interferon. He worked for Johnson & Johnson as project manager and was responsible for preclinical and Phase II product development projects in the oncology franchise. In addition he was involved in in-licensing activities for Johnson & Johnson. Since 2000 he gained experience in several small start-up and early stage companies in the Netherlands. He was director business development at Pepscan Systems and managing director of Macrozyme. At Macrozyme Edward was responsible for the complete pre-clinical development of a new oral anti-diabetic compound that under his responsibility was successfully partnered with Genzyme Inc. in 2005. Since 2006 he is managing partner of Biogeneration Ventures and serves on the board of Progentix Orthobiology BV, NovioGendix BV and Arcarios BV, Edward holds a M.Sc in chemistry from the University of Utrecht and a M.Sc in Biochemical Engineering from the University of Delft. Expertise: Financing, IP, Business Development, Early stage companies, Drug Development, Process Engineering. Interests: Therapeutics, Drug discovery, Diagnostics, Medical Devices, Food. Peter van Dongen Function: Account manager Organisation: Netherlands Patent Office Email: Peter.firstname.lastname@example.org Short biography: Since 1986 Van Dongen worked at several organisations and companies in various positions, bearing the responsibility for technology, product and market development both in The Netherlands and abroad. The organisation of R&D, Transfer of Technology, business and market development of products and processes using of Intellectual Property Rights ( IPR eg. patents) have been part of his responsibilities. Since 2001, Van Dongen is account manager working at the Netherlands Patent Office, responsible for the organisation of pre- filing searches, IP lectures and workshops at universities and Technology Institutes Between 1993 – 2000 he has worked as VP Europe at Trojan Technologies Inc., a manufacturer of UV desinfection reactors, and as member of the management team and project engineer at SAWA Consulting Engineers / Arcadis in the sector of water treatment and water technology. From 1986 - 1993 he worked as a self employed consultant in an EU funded programme for organic fertilizers and as project engineer with the Food and Agricultural Organisation of the UN in soil fertility and water management in projects in Africa and South America. He started his career writing a PhD research proposal, for micro- biotechnology research on the use of enzymes and micro- organisms to fix nitrogen in the soil in the rooting zone of plants in order to stimulate plant growth and yields, to be executed at the Wageningen University and sponsored by DSM. Expertise: IPR, Business development in water technology and green / agricultural LS. Interests: Food, Devices, New medicines. Marcel van Kooij Function: Patent attorney Organisation: Arnold & Siedsma Email: email@example.com Short biography: Marcel has a Master‟s degree in biology from the University of Utrecht, where he specialized in molecular biology, molecular genetics and biochemistry. Marcel completed his PhD in biomedicine at the University of Groningen, concentrating on the development of a vaccine against herpes simplex virus. Before joining Arnold + Siedsma, Marcel worked as a post-doctorate at the Netherlands Cancer Institute, specialising in the genetics of lung cancer. Marcel‟s patent practise deals mainly with biotechnology, biochemistry and pharmaceuticals. Marcel is also a CEIPI tutor. Expertise: IP Bart Swinkels Function: European Patent Attorney Organisation: Nederlandsch Octrooibureau Email: firstname.lastname@example.org Short biography: Bart Swinkels is a partner at Nederlandsch Octrooibureau and has more than 17 years experience the patent profession. Prior to joining Nederlandsch Octrooibureau in 2000 Bart headed the IP department of the Pharming Group in Leiden (Netherlands) and he worked as in-house patent attorney with DSM/Gist- brocades in Delft (Netherlands). Before entering the patent profession Bart worked as a molecular biologist in both academic and industrial research settings at Gist-brocades, the University of California at San Diego and the Netherlands Cancer Institute. Bart holds a M.Sc. in (bio)chemistry (cum laude, 1985) from the University of Amsterdam and a Ph.D. in molecular biology under Prof. Piet Borst, also from the University of Amsterdam (1989). He qualified as Netherlands and European Patent Attorney in 1997. Expertise: Bart practices as patent attorney in all areas of biotechnology especially molecular biology, genomics, biochemistry, bioinformatics, immunology, metabolic engineering, transgenic animals, stem cells, classical and molecular plant genetics. He has extensive experience in drafting prosecuting and litigating complex patent and applications, and he frequently advises biotech firms (from start-up to established) on their IP strategy and patent portfolio management. Interests: Vaccines, Gene Therapies, Drug discovery, Diagnostics, Antibody technology, Protein production, Metabolic engineering, Biofuels, Systems biology, etc. Carine van den Brink Function: Lawyer and partner Email: Carine.email@example.com Short biography: Carine received her law degree in 1989 and a medical degree in 1987. She worked for the law firm Stibbe from 1990 to 1997 after which she joined Pharming as senior legal counsel and secretary to the board. In 2002 she started her own lawfirm, entirely focused on companies and institutes in the life science. Her client base includes many Dutch biotech companies (pharma and agro), hospitals and other knowledge institutes. She is a member of the supervisory board of Profibrix B.V. and member of the NGI pre-seed committee. Carine lectures at the University of Leiden and at the NIABA master class. Expertise: Carine has vast expertise in licensing contracts, spin-out constructions, equity financing of technostarters, operational contracts such as clinical trials and manufacturing and strategic collaborations (R&D contracts, partnerships, etc.). Carine‟s combination of legal expertise, medical background and knowledge of the biotech and healthcare market give her advices an invaluable practical utility. Maurits Westerik Function: Attorney-at-law Organisation: Bird & Bird LLP Email: Maurits.firstname.lastname@example.org Short biography: Maurits Westerik is a member of the Intellectual Property and Information Technology Groups of Bird & Bird in the Netherlands. He specialises in intellectual property, especially in technology-related IP and life sciences-related patent cases. Maurits studied law at the University of Leiden and is a graduate of the international programme of the Institute for Political Sciences (SciencePo) in Paris. He has been an IP/IT lawyer in Amsterdam since 2004, before joining Bird & Bird in 2007. Maurits is an active speaker on IP strategy and also teaches IP law and international IP strategy at the Universities of Leiden and Amsterdam. Expertise: IP, IP strategy, research and collaboration agreements, licensing, patent litigation. Interests: Software (BioInformatics), know-how, dual licensing (combining open & closed source software). Eric Claassen Function: CEO Organisation: Vironovative BV Email: email@example.com Short biography: Eric is 10% academic and 90% entrepreneur. He is also the winner of the 2009 Dutch 1 million Euro NGI Valorisation Award for „Excellent deal making with Industry”. Furthermore he is active as: President of the Supervisory Board of AM-Pharma BV, Dynomics BV, EC3MA BV,HOPE BV and DC4U BV. CEO/Statutory director of ViroNovative BV Coronovative BV, Viroclinics BV (all in Rotterdam with prof. dr. ADME Osterhaus) and ML Consultancy BV. He is a member of the SAB of ABN-AMRO life science venture fund FORBION and Emergent Biosolutions (Biological Warfare vaccines). He was chairman (level 1 CTS clearance) of PG32 on Handheld detection of Biological Weapons. Among various memberships of committees he is an elected member of the Netherlands Academy of Technology and Innovation (AcTI.nl) and the Dutch Health Council (Gezondheidsraad). He was recently appointed as professor (0 FTE) in “Knowledge Valorisation in the Life Sciences” at Dept. Virology Erasmus MC in Rotterdam where he was professor of Immunology since 1994. In 2005 he was appointed as “Entrepreneur in Residence” at the RSM (Rotterdam School of Management; bedrijfskunde). In 2001 he was appointed as the first Biopartner professor "Entrepreneurship in the Life Sciences" on behalf of the Ministry of Economic Affairs at the Vrije Universiteit Amsterdam (This chair, which he still holds, was transformed in 2005 to “Business management and Entrepreneurship in Health & Life Sciences 0.1 FTE). He is also a visiting professor for the Immunology courses at Institut Pasteur/University of Paris since 1992. Expertise: Financing, Business Development in Immunology and Virology. Peter Sijmons Function: Director Organisation: Szienz Email: firstname.lastname@example.org Short biography: Peter Sijmons is founder and director of Szienz, a software company for the life science industry. The flagship product for Szienz is LabScores, a Laboratory Information Management System (LIMS) that originated and was developed over the years for CatchMabs BV (see below) and was later rewritten into a commercial software package. Prior to Szienz, he was founder and CEO of CatchMabs BV, a biotech company in Wageningen, the Netherlands, that focussed on the development of molecular affinity bodies for industrial applications of affinity chromatography and where the Tsunami Bioreactor was invented. Due to lack of investors, all activities of CatchMabs had to be terminated in the summer of 2006. From 1997-1999 he was Research Director of the Institute for Agrotechnological Research (ATO-DLO) in Wageningen and played a pivotal role in the legal structure of technology transfer from Wageningen University and Research Centre to the private industry. He joined the management team of ATO-DLO in 1994 as head of the department for Postharvest Physiology and Molecular Biology and was appointed division manager (Fresh Produce) in 1995. In 1987, he became member of the start-up team of Mogen International, the first plant biotechnology company in the Netherlands. For a period of 7 years, he had several scientific and management positions at Mogen. Sijmons has a PhD in PlantPhysiology from the Univ of Amsterdam. Expertise: Business Development, Business Plan, startup coaching. Interests: LIMS systems, custom software development for biotech companies. Tolleiv Trimborn Function: CEO Organisation: Arcarios Email: email@example.com Short biography: Tolleiv is the founder and CEO of Arcarios BV, a drug development company in he field of bone and joint diseases. Arcarios was formed through the merger of Therosteon BV, a Dutch biotech company and TR Therapeutics a Belgium company in 2010. Arcarios raised 4.1 mln EUR seed funding and aims to develop two preclinical programs upto proof of concept in humans. At present Arcarios employs 11 FTE. Tolleiv has a combined commercial and scientific background. Previously he held various positions at DNage. First he was responsible for business development and day-to-day operations and after the acquisition of DNage by Pharming in 2006 he became general manager of DNage. Prior to DNage he worked at Life Science Partners (LSP), a venture capital fund in Amsterdam. Tolleiv holds a PhD in molecular biology from the Erasmus Medical Center and was a post-doctoral fellow at the Howard Hughes Medical Institute at Stanford University, Palo Alto, (CA, USA). Expertise: Business development, Biotech start-up (strategy and financing). Interests: Biologicals, Small molecules, Drug discovery, Bone and joint diseases. Arjan Bisseling Function: Tax Advisor Organisation: AsjesBisseling Belastingadviseurs BV Email: firstname.lastname@example.org Short biography: Up until 2010 I was tax manager at PricewaterhouseCoopers (pwc). As a member of the Life Science core team within pwc I advised companies varying from small biotech companies to big pharmaceuticals. As of 1 January 2011 I‟ve started my own business (AsjesBisseling Belastingadviseurs BV) with 3 other former pwc colleagues. It is our aim to build a high level boutique office focussing on, amongst others, innovative industry (and particularly the Life Science industry). Expertise: Providing tax advise to companies and individuals on corporate income tax, personal income tax and wage tax issues. Special expertise in the Life Sciences industry. For start-up (up until phase I) Life Science companies we agreed on rulings with the Dutch Tax Authorities about a very limited value of the company for (personal income and wage) tax purposes. Furthermore, we negotiated favorable rulings for the application of the Dutch innovation box (income from newly developed IP taxed at 5%). Interests: No specific areas of interest. We are happy to assist all kind of Life Science companies, i.e. in the field of Therapies, Drug discovery, Diagnostics, Medical Devices, Biodiversity, Food, etc. Lammert Landman Function: Senior Manager Organisation: KPMG Email: email@example.com Short biography: Master degree in Business Economics at the University of Amsterdam (UvA). In 2000 I started at KPMG. KPMG is a global network of professional services firms providing Audit, Tax and Advisory services. KPMG combines a multi-disciplinary approach with deep, practical industry knowledge to help clients meet challenges and respond to opportunities. Expertise: Certified Public Auditor (Registeraccountant) with broad experience in audit and advisory service to both national and international companies (trade companies, service providers, non-profit organizations). Key words: Accounting, Tax, IT, administrative organization, financing, cash flow forecasting. Interests: Drug discovery and Medical Devices. Math Kohnen Function: Business Coach Organisation: eNovITe Email: firstname.lastname@example.org Short biography: Obtained a PhD (cum laude) in organic chemistry from Technical University Delft. Started a nine-year career with Shell as a researcher in Petroleum Geochemistry. Designed and managed Shell's GameChanger program: a seed-capital process to drive business growth by unleashing internal and external start-ups. Assisted Shell‟s Executive Committee in setting direction for the Group as a Corporate Strategist. Became an independent Strategy/Innovation consultant working together in a networked fashion with many management consultants. For last ten years assisted a broad range of client companies in reinventing their core business, discovering new market opportunities and developing sound growth strategies. Experience gathered in following industries: Advanced Materials, Automotive, FMCG, IT, Metals and Mining, Oil & Gas, Plastics, Pulp & Paper, Recycling, Skin & Beauty Care and Telecom. Coaches entrepreneurs to progress business/technology ideas into compelling business plans and beyond. Designs and facilitates with enthusiasm NGI‟s Venture Challenge. Expertise: Defining and testing compelling value propositions for customers, suppliers and partners and deciding on the right position in the value web. Creating winning business models for Life-science start-ups by applying the experience from cross-industry examples. Successful companies, regardless their industry or technology, share common elements in their business models. Mapping the short term and long term development paths of a start-up. Creating sound presentations/pitches/plans to attract investors/partners. Interests: Regardless industry or technology I love to play “the mental chess game” with the many interrelated choices a start-up has to make towards a successful business. Hans Le Fever Function: Business Coach Organisation: eNovITe Email: email@example.com Short biography: Hans Le Fever (PhD Experimental Physics, Leiden) He worked for Shell in a variety of advisory and line management jobs on the interface of business and IT with focus on creating sustainable business improvement. He left in 2002 and became the (co-) founder of several knowledge based companies. His philosophy: "You can learn from anyone." Which he did from excellent international consultants and which he passes on as secretary of the Society of Organisational Learning. He teaches the importance of IT in Business as Adjoint Professor at Leiden University. Expertise: value proposition, business model, information management, organizational development, performance management. Interests: General interest in “how to grow a company”. Critical issues in the start-up phase. Arnoud Dijkstra Function: Chief Business Officer Organisation: Profibrix Email: firstname.lastname@example.org Short biography: In April 2011, Arnoud Dijkstra was appointed Chief Business Officer of Profibirix, a Leiden-based biotech company that is active in the field of hemostasis. Before joining Profibrix, Arnoud was CBO and member of the executive management team of the Dutch/British biotech company PanGenetics where he was responsible for Business Development and was a member of the team that successfully sold the company‟s main asset to Abbott. Before returning to the Netherlands in 2006, Arnoud spent 14 years in the Swiss pharmaceutical and biotech industry, at Hoffmann-La Roche, where he spent eight years and held several positions in research management, at Morphochem, where he was VP Operations of the Basel branch, and at Actelion Pharmaceuticals, where he was Director Business Development. Expertise: Business Development, Licensing, Investor Relations, Start-up/management of biotech companies. Interests: Drug discovery, enabling technology, business development, financing.
Pages to are hidden for
"Programme Wednesday June"Please download to view full document